Computational modeling and experimental validation of the EPI-X4/CXCR4 complex allows rational design of small peptide antagonists
Combining molecular modeling and in vitro bioassays, Sokkar et al. provide an understanding of how EPI-X4, an endogenous peptide antagonist, interacts with its receptor CXCR4. With computational model, validated by mutagenesis studies, they design a series of derivatives with optimized receptor anta...
Guardado en:
Autores principales: | Pandian Sokkar, Mirja Harms, Christina Stürzel, Andrea Gilg, Gönül Kizilsavas, Martina Raasholm, Nico Preising, Manfred Wagner, Frank Kirchhoff, Ludger Ständker, Gilbert Weidinger, Benjamin Mayer, Jan Münch, Elsa Sanchez-Garcia |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f993d3d26776456ebe0fc89bf8e4a5df |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
EPI Cuestionario de personalidad EPI: Manual
por: Eysenck, Hans Jurgen, et al.
Publicado: (1994) -
A novel CXCR4-targeted near-infrared (NIR) fluorescent probe (Peptide R-NIR750) specifically detects CXCR4 expressing tumors
por: Sara Santagata, et al.
Publicado: (2017) -
Natural amines inhibit activation of human plasmacytoid dendritic cells through CXCR4 engagement
por: Nikaïa Smith, et al.
Publicado: (2017) -
Stromal derived factor-1 (SDF-1) and its receptors CXCR4 and CXCR7 in endometrial cancer patients.
por: Malgorzata Walentowicz-Sadlecka, et al.
Publicado: (2014) -
Type 1 diabetes patients increase CXCR4+ and CXCR7+ haematopoietic and endothelial progenitor cells with exercise, but the response is attenuated
por: Guy S. Taylor, et al.
Publicado: (2021)